Kristine Erlandson
Concepts (503)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 207 | 2026 | 3215 | 31.830 |
Why?
| | Frailty | 40 | 2026 | 208 | 14.680 |
Why?
| | Aging | 52 | 2026 | 1996 | 7.510 |
Why?
| | Sarcopenia | 14 | 2026 | 100 | 5.910 |
Why?
| | Exercise | 27 | 2026 | 2213 | 4.970 |
Why?
| | Anti-HIV Agents | 27 | 2026 | 914 | 4.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2026 | 449 | 4.000 |
Why?
| | HIV Integrase Inhibitors | 10 | 2026 | 80 | 3.870 |
Why?
| | Anti-Retroviral Agents | 16 | 2025 | 250 | 3.770 |
Why?
| | Antiretroviral Therapy, Highly Active | 15 | 2021 | 278 | 3.680 |
Why?
| | Middle Aged | 152 | 2026 | 36619 | 3.590 |
Why?
| | Body Composition | 17 | 2026 | 689 | 3.410 |
Why?
| | Muscle, Skeletal | 15 | 2026 | 1818 | 3.330 |
Why?
| | Exercise Therapy | 9 | 2026 | 488 | 3.220 |
Why?
| | Cytomegalovirus Infections | 7 | 2026 | 206 | 3.180 |
Why?
| | Glucagon-Like Peptides | 4 | 2026 | 76 | 3.150 |
Why?
| | Aged | 102 | 2026 | 26432 | 2.950 |
Why?
| | Male | 175 | 2026 | 73396 | 2.880 |
Why?
| | Accidental Falls | 12 | 2026 | 227 | 2.810 |
Why?
| | HIV-1 | 18 | 2024 | 913 | 2.790 |
Why?
| | Humans | 249 | 2026 | 146342 | 2.720 |
Why?
| | Osteoporosis | 7 | 2025 | 240 | 2.710 |
Why?
| | Quinolines | 4 | 2026 | 191 | 2.600 |
Why?
| | Cardiovascular Diseases | 18 | 2026 | 2219 | 2.570 |
Why?
| | Inflammation | 20 | 2026 | 2919 | 2.540 |
Why?
| | Hand Strength | 9 | 2026 | 149 | 2.410 |
Why?
| | Acquired Immunodeficiency Syndrome | 6 | 2023 | 238 | 2.350 |
Why?
| | Female | 149 | 2026 | 79499 | 2.340 |
Why?
| | Weight Gain | 12 | 2026 | 562 | 2.300 |
Why?
| | Walking Speed | 8 | 2025 | 53 | 2.200 |
Why?
| | Fatty Liver | 3 | 2026 | 252 | 2.170 |
Why?
| | Adult | 106 | 2026 | 41087 | 2.140 |
Why?
| | Healthy Aging | 4 | 2025 | 44 | 2.060 |
Why?
| | Cohort Studies | 38 | 2026 | 6077 | 2.000 |
Why?
| | Bone Density | 6 | 2025 | 494 | 1.850 |
Why?
| | Growth Hormone-Releasing Hormone | 4 | 2026 | 19 | 1.780 |
Why?
| | Adipose Tissue | 7 | 2020 | 642 | 1.780 |
Why?
| | Cytomegalovirus | 7 | 2026 | 172 | 1.680 |
Why?
| | Risk Factors | 41 | 2026 | 10921 | 1.660 |
Why?
| | Cognitive Dysfunction | 5 | 2026 | 481 | 1.650 |
Why?
| | High-Intensity Interval Training | 4 | 2026 | 45 | 1.520 |
Why?
| | Absorptiometry, Photon | 9 | 2026 | 278 | 1.490 |
Why?
| | Biomarkers | 20 | 2026 | 4340 | 1.480 |
Why?
| | Quality of Life | 16 | 2026 | 3200 | 1.460 |
Why?
| | HIV | 14 | 2023 | 249 | 1.380 |
Why?
| | Tenofovir | 6 | 2026 | 300 | 1.320 |
Why?
| | Lipopolysaccharide Receptors | 4 | 2022 | 88 | 1.270 |
Why?
| | Cross-Sectional Studies | 29 | 2026 | 5899 | 1.210 |
Why?
| | Hospitalization | 7 | 2026 | 2475 | 1.200 |
Why?
| | Frail Elderly | 9 | 2026 | 141 | 1.180 |
Why?
| | Obesity | 8 | 2026 | 3131 | 1.150 |
Why?
| | Obesity, Abdominal | 2 | 2019 | 48 | 1.100 |
Why?
| | Pyridones | 3 | 2026 | 210 | 1.100 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 1101 | 1.100 |
Why?
| | Disease Management | 5 | 2020 | 651 | 1.050 |
Why?
| | Comorbidity | 17 | 2024 | 1665 | 1.040 |
Why?
| | Activities of Daily Living | 5 | 2023 | 442 | 1.040 |
Why?
| | Rosuvastatin Calcium | 3 | 2015 | 21 | 1.020 |
Why?
| | Body Mass Index | 12 | 2026 | 2458 | 1.010 |
Why?
| | Cognition | 6 | 2026 | 1292 | 1.000 |
Why?
| | Fractures, Bone | 4 | 2024 | 436 | 0.990 |
Why?
| | Mass Screening | 2 | 2025 | 1307 | 0.980 |
Why?
| | Muscles | 4 | 2024 | 330 | 0.970 |
Why?
| | Bone and Bones | 3 | 2026 | 319 | 0.940 |
Why?
| | Longitudinal Studies | 16 | 2026 | 3017 | 0.930 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 60 | 0.930 |
Why?
| | Prospective Studies | 24 | 2025 | 8123 | 0.920 |
Why?
| | Adiposity | 4 | 2019 | 533 | 0.900 |
Why?
| | Aged, 80 and over | 19 | 2026 | 8391 | 0.870 |
Why?
| | Psoas Muscles | 1 | 2025 | 24 | 0.860 |
Why?
| | Metabolic Diseases | 2 | 2023 | 114 | 0.840 |
Why?
| | Self Efficacy | 4 | 2024 | 418 | 0.830 |
Why?
| | DNA, Mitochondrial | 3 | 2021 | 212 | 0.820 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 769 | 0.820 |
Why?
| | Alanine | 2 | 2026 | 171 | 0.820 |
Why?
| | Muscle Strength | 4 | 2022 | 340 | 0.820 |
Why?
| | HIV Long-Term Survivors | 2 | 2020 | 3 | 0.790 |
Why?
| | Motor Activity | 4 | 2016 | 704 | 0.790 |
Why?
| | Advance Care Planning | 3 | 2021 | 244 | 0.790 |
Why?
| | Cigarette Smoking | 1 | 2025 | 103 | 0.780 |
Why?
| | Physical Fitness | 2 | 2015 | 209 | 0.770 |
Why?
| | HIV Seropositivity | 5 | 2024 | 118 | 0.770 |
Why?
| | Neurocognitive Disorders | 3 | 2019 | 34 | 0.760 |
Why?
| | HIV Integrase | 1 | 2024 | 74 | 0.760 |
Why?
| | Telemedicine | 2 | 2023 | 966 | 0.750 |
Why?
| | CD4 Lymphocyte Count | 7 | 2020 | 280 | 0.740 |
Why?
| | Body Weight | 3 | 2016 | 968 | 0.740 |
Why?
| | Coronary Artery Disease | 3 | 2023 | 751 | 0.730 |
Why?
| | Advance Directives | 2 | 2021 | 89 | 0.700 |
Why?
| | Social Determinants of Health | 1 | 2026 | 317 | 0.700 |
Why?
| | Malnutrition | 1 | 2023 | 87 | 0.690 |
Why?
| | Telerehabilitation | 1 | 2022 | 49 | 0.680 |
Why?
| | Hypoglycemic Agents | 3 | 2026 | 1412 | 0.680 |
Why?
| | Organ Transplantation | 1 | 2024 | 244 | 0.670 |
Why?
| | United States | 24 | 2026 | 16136 | 0.660 |
Why?
| | Double-Blind Method | 6 | 2026 | 2070 | 0.660 |
Why?
| | Lipodystrophy | 2 | 2023 | 12 | 0.660 |
Why?
| | Atazanavir Sulfate | 2 | 2020 | 41 | 0.660 |
Why?
| | Antibodies, Viral | 3 | 2026 | 689 | 0.660 |
Why?
| | Raltegravir Potassium | 1 | 2020 | 18 | 0.640 |
Why?
| | Geriatric Assessment | 5 | 2026 | 244 | 0.640 |
Why?
| | Prevalence | 14 | 2026 | 2861 | 0.640 |
Why?
| | Odds Ratio | 8 | 2022 | 1077 | 0.640 |
Why?
| | Guideline Adherence | 1 | 2025 | 594 | 0.640 |
Why?
| | Darunavir | 1 | 2020 | 20 | 0.640 |
Why?
| | Heart Rate | 1 | 2024 | 846 | 0.640 |
Why?
| | Hyperlipidemias | 1 | 2021 | 120 | 0.620 |
Why?
| | Vaccination Coverage | 2 | 2018 | 106 | 0.620 |
Why?
| | Depression | 3 | 2025 | 1575 | 0.620 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 125 | 0.610 |
Why?
| | Metabolic Syndrome | 1 | 2024 | 364 | 0.610 |
Why?
| | Occupational Therapy | 1 | 2022 | 110 | 0.610 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2024 | 265 | 0.610 |
Why?
| | Placebos | 5 | 2025 | 192 | 0.600 |
Why?
| | Mobile Applications | 1 | 2022 | 196 | 0.590 |
Why?
| | Herpes Zoster Vaccine | 2 | 2018 | 154 | 0.590 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 3 | 2019 | 9 | 0.580 |
Why?
| | Viral Load | 7 | 2024 | 526 | 0.580 |
Why?
| | Triazoles | 3 | 2026 | 190 | 0.580 |
Why?
| | Interleukin-10 | 1 | 2021 | 310 | 0.580 |
Why?
| | Haplotypes | 2 | 2020 | 506 | 0.560 |
Why?
| | Sex Factors | 5 | 2025 | 2107 | 0.550 |
Why?
| | Retrospective Studies | 18 | 2026 | 17438 | 0.550 |
Why?
| | Health Promotion | 1 | 2024 | 786 | 0.530 |
Why?
| | Herpes Zoster | 2 | 2018 | 318 | 0.520 |
Why?
| | Guidelines as Topic | 2 | 2019 | 267 | 0.520 |
Why?
| | Plague | 2 | 2015 | 60 | 0.520 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1137 | 0.520 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 320 | 0.510 |
Why?
| | Sexual and Gender Minorities | 2 | 2021 | 269 | 0.510 |
Why?
| | Lung | 4 | 2026 | 4122 | 0.500 |
Why?
| | Immunosenescence | 1 | 2017 | 5 | 0.500 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 115 | 0.500 |
Why?
| | Logistic Models | 6 | 2025 | 2126 | 0.490 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 24 | 0.480 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 314 | 0.480 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 228 | 0.480 |
Why?
| | Hormones | 1 | 2017 | 134 | 0.470 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 3 | 0.470 |
Why?
| | Academic Medical Centers | 1 | 2019 | 561 | 0.470 |
Why?
| | Attitude to Health | 1 | 2019 | 421 | 0.460 |
Why?
| | Yersinia pestis | 2 | 2015 | 45 | 0.460 |
Why?
| | Age Factors | 12 | 2026 | 3347 | 0.450 |
Why?
| | Muscular Atrophy | 1 | 2016 | 88 | 0.440 |
Why?
| | Immunoglobulin G | 4 | 2026 | 901 | 0.440 |
Why?
| | RNA, Viral | 3 | 2019 | 693 | 0.440 |
Why?
| | Integrases | 4 | 2024 | 117 | 0.430 |
Why?
| | Fluorobenzenes | 1 | 2015 | 17 | 0.430 |
Why?
| | Monocytes | 2 | 2015 | 538 | 0.430 |
Why?
| | Biomedical Research | 4 | 2024 | 729 | 0.430 |
Why?
| | Cannabis | 2 | 2023 | 521 | 0.430 |
Why?
| | Case-Control Studies | 5 | 2026 | 3647 | 0.430 |
Why?
| | Treatment Outcome | 11 | 2026 | 11821 | 0.420 |
Why?
| | Plasma | 2 | 2018 | 222 | 0.420 |
Why?
| | Weight Loss | 4 | 2026 | 858 | 0.420 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 143 | 0.420 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.420 |
Why?
| | Colorado | 8 | 2026 | 4595 | 0.410 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 12 | 0.410 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.410 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.410 |
Why?
| | Adipocytes | 1 | 2016 | 223 | 0.410 |
Why?
| | Pilot Projects | 5 | 2026 | 1888 | 0.410 |
Why?
| | Anticholesteremic Agents | 1 | 2015 | 156 | 0.400 |
Why?
| | Microbiota | 1 | 2021 | 725 | 0.390 |
Why?
| | Polypharmacy | 3 | 2024 | 94 | 0.390 |
Why?
| | Syphilis | 1 | 2014 | 39 | 0.390 |
Why?
| | Sarcoma, Kaposi | 1 | 2014 | 83 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2786 | 0.390 |
Why?
| | Mycoses | 1 | 2014 | 87 | 0.390 |
Why?
| | Motivation | 4 | 2024 | 605 | 0.390 |
Why?
| | Decision Making | 1 | 2021 | 993 | 0.380 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2014 | 130 | 0.380 |
Why?
| | Retinal Detachment | 1 | 2014 | 74 | 0.380 |
Why?
| | Self Report | 5 | 2022 | 870 | 0.380 |
Why?
| | Adenine | 2 | 2026 | 339 | 0.370 |
Why?
| | Incidence | 6 | 2026 | 2936 | 0.360 |
Why?
| | Coinfection | 3 | 2021 | 143 | 0.360 |
Why?
| | Transplant Recipients | 2 | 2024 | 177 | 0.360 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 189 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2026 | 1763 | 0.350 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.350 |
Why?
| | Proportional Hazards Models | 5 | 2026 | 1331 | 0.340 |
Why?
| | Pyrimidines | 1 | 2015 | 532 | 0.330 |
Why?
| | Pandemics | 4 | 2023 | 1707 | 0.330 |
Why?
| | Benzoxazines | 3 | 2023 | 31 | 0.330 |
Why?
| | Cyclopropanes | 3 | 2023 | 83 | 0.320 |
Why?
| | Sulfonamides | 1 | 2015 | 594 | 0.320 |
Why?
| | Lamivudine | 3 | 2017 | 63 | 0.320 |
Why?
| | Vitamin D | 1 | 2014 | 402 | 0.320 |
Why?
| | Alkynes | 3 | 2023 | 67 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2025 | 410 | 0.310 |
Why?
| | Mental Health | 3 | 2024 | 779 | 0.310 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1942 | 0.310 |
Why?
| | Metformin | 2 | 2024 | 328 | 0.310 |
Why?
| | Epigenesis, Genetic | 2 | 2026 | 712 | 0.300 |
Why?
| | Muscle Weakness | 2 | 2020 | 93 | 0.300 |
Why?
| | Survival Analysis | 4 | 2025 | 1378 | 0.290 |
Why?
| | Subcutaneous Fat | 5 | 2021 | 80 | 0.290 |
Why?
| | Substance-Related Disorders | 3 | 2026 | 1100 | 0.290 |
Why?
| | Veterans | 4 | 2023 | 1650 | 0.290 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 931 | 0.280 |
Why?
| | Disease Progression | 4 | 2024 | 2867 | 0.280 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2026 | 1150 | 0.280 |
Why?
| | Interleukin-6 | 3 | 2021 | 784 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 2 | 2021 | 79 | 0.270 |
Why?
| | Virginiamycin | 1 | 2008 | 3 | 0.270 |
Why?
| | Emtricitabine | 2 | 2021 | 209 | 0.270 |
Why?
| | Focus Groups | 3 | 2025 | 588 | 0.270 |
Why?
| | Energy Metabolism | 1 | 2014 | 930 | 0.270 |
Why?
| | Vancomycin Resistance | 1 | 2008 | 16 | 0.270 |
Why?
| | Oxazolidinones | 1 | 2008 | 16 | 0.270 |
Why?
| | Enterococcus | 1 | 2008 | 22 | 0.260 |
Why?
| | Canada | 4 | 2025 | 432 | 0.260 |
Why?
| | Acetamides | 1 | 2008 | 42 | 0.260 |
Why?
| | United Kingdom | 3 | 2025 | 377 | 0.260 |
Why?
| | Surveys and Questionnaires | 10 | 2024 | 6073 | 0.260 |
Why?
| | Social Support | 2 | 2024 | 646 | 0.260 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 417 | 0.250 |
Why?
| | Fatigue | 4 | 2026 | 363 | 0.250 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2008 | 72 | 0.250 |
Why?
| | Body Fat Distribution | 3 | 2019 | 47 | 0.250 |
Why?
| | Insulin Resistance | 1 | 2015 | 1247 | 0.240 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2026 | 40 | 0.240 |
Why?
| | Electronic Health Records | 2 | 2025 | 1210 | 0.240 |
Why?
| | Resistance Training | 2 | 2026 | 186 | 0.240 |
Why?
| | Anthropometry | 2 | 2017 | 204 | 0.240 |
Why?
| | Loneliness | 2 | 2024 | 69 | 0.240 |
Why?
| | Washington | 1 | 2026 | 157 | 0.230 |
Why?
| | Residence Characteristics | 2 | 2026 | 385 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 928 | 0.230 |
Why?
| | Zidovudine | 2 | 2017 | 75 | 0.230 |
Why?
| | Radiography, Abdominal | 2 | 2017 | 44 | 0.220 |
Why?
| | Bacteremia | 1 | 2008 | 218 | 0.220 |
Why?
| | Young Adult | 13 | 2025 | 14330 | 0.220 |
Why?
| | Life Expectancy | 3 | 2020 | 72 | 0.220 |
Why?
| | Independent Living | 3 | 2025 | 114 | 0.220 |
Why?
| | Risk Assessment | 6 | 2024 | 3712 | 0.220 |
Why?
| | Patient Dropouts | 1 | 2025 | 65 | 0.220 |
Why?
| | Forced Expiratory Volume | 1 | 2026 | 451 | 0.210 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 60 | 0.210 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.200 |
Why?
| | Seroepidemiologic Studies | 1 | 2024 | 171 | 0.200 |
Why?
| | Respiratory Function Tests | 1 | 2026 | 543 | 0.200 |
Why?
| | Thigh | 2 | 2022 | 49 | 0.200 |
Why?
| | Community Participation | 1 | 2025 | 128 | 0.200 |
Why?
| | Disability Evaluation | 3 | 2022 | 297 | 0.200 |
Why?
| | Substance Abuse, Intravenous | 1 | 2025 | 131 | 0.200 |
Why?
| | Methadone | 1 | 2025 | 130 | 0.200 |
Why?
| | Drug Substitution | 1 | 2024 | 62 | 0.200 |
Why?
| | Ireland | 4 | 2025 | 33 | 0.200 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 172 | 0.200 |
Why?
| | Blood Glucose | 1 | 2014 | 2360 | 0.200 |
Why?
| | Qualitative Research | 5 | 2025 | 1734 | 0.200 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2025 | 150 | 0.200 |
Why?
| | Urinary Tract Infections | 1 | 2026 | 209 | 0.200 |
Why?
| | HIV Protease Inhibitors | 2 | 2021 | 69 | 0.190 |
Why?
| | Cost of Illness | 1 | 2026 | 323 | 0.190 |
Why?
| | Chronic Disease | 5 | 2023 | 1827 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3926 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1036 | 0.190 |
Why?
| | Prognosis | 3 | 2021 | 4351 | 0.190 |
Why?
| | Medication Adherence | 2 | 2018 | 535 | 0.190 |
Why?
| | Organizations | 1 | 2022 | 28 | 0.180 |
Why?
| | Flow Cytometry | 1 | 2026 | 1163 | 0.180 |
Why?
| | NF-kappa B | 1 | 2026 | 674 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2023 | 72 | 0.180 |
Why?
| | Computed Tomography Angiography | 1 | 2023 | 151 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 207 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 376 | 0.180 |
Why?
| | DNA Methylation | 2 | 2026 | 725 | 0.180 |
Why?
| | Homosexuality, Male | 2 | 2021 | 231 | 0.170 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 15 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2023 | 245 | 0.170 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 39 | 0.170 |
Why?
| | Coronary Angiography | 1 | 2023 | 325 | 0.170 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 57 | 0.170 |
Why?
| | Succinic Acid | 1 | 2021 | 46 | 0.170 |
Why?
| | Counseling | 1 | 2024 | 406 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.170 |
Why?
| | Postural Balance | 1 | 2024 | 249 | 0.170 |
Why?
| | North America | 1 | 2022 | 300 | 0.170 |
Why?
| | Isoniazid | 1 | 2021 | 71 | 0.170 |
Why?
| | Immunity | 1 | 2022 | 141 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 442 | 0.160 |
Why?
| | Prediabetic State | 1 | 2024 | 250 | 0.160 |
Why?
| | Sequence Alignment | 1 | 2021 | 360 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2026 | 2623 | 0.160 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 71 | 0.160 |
Why?
| | Metabolomics | 1 | 2026 | 738 | 0.160 |
Why?
| | Italy | 1 | 2020 | 118 | 0.160 |
Why?
| | Epidemics | 1 | 2021 | 97 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.160 |
Why?
| | Program Evaluation | 1 | 2024 | 952 | 0.160 |
Why?
| | Feces | 2 | 2025 | 496 | 0.160 |
Why?
| | Hospitals, Teaching | 1 | 2020 | 121 | 0.150 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 634 | 0.150 |
Why?
| | Socioeconomic Factors | 2 | 2016 | 1327 | 0.150 |
Why?
| | Death | 1 | 2021 | 129 | 0.150 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 589 | 0.150 |
Why?
| | Actigraphy | 1 | 2020 | 148 | 0.150 |
Why?
| | Energy Intake | 1 | 2022 | 507 | 0.150 |
Why?
| | Lipoproteins, LDL | 2 | 2022 | 119 | 0.150 |
Why?
| | Self Care | 2 | 2021 | 396 | 0.150 |
Why?
| | Cause of Death | 2 | 2019 | 456 | 0.150 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 307 | 0.150 |
Why?
| | Kidney Transplantation | 1 | 2026 | 735 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2021 | 429 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 516 | 0.150 |
Why?
| | Blood Pressure | 1 | 2026 | 1765 | 0.140 |
Why?
| | Alcoholism | 1 | 2026 | 830 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 330 | 0.140 |
Why?
| | Liver | 2 | 2026 | 1864 | 0.140 |
Why?
| | Bone Diseases | 1 | 2019 | 60 | 0.140 |
Why?
| | Psychotropic Drugs | 1 | 2019 | 75 | 0.140 |
Why?
| | Waist Circumference | 1 | 2019 | 142 | 0.140 |
Why?
| | Lumbar Vertebrae | 2 | 2018 | 260 | 0.140 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 61 | 0.140 |
Why?
| | Survivors | 1 | 2022 | 526 | 0.140 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2921 | 0.130 |
Why?
| | Metagenome | 1 | 2019 | 127 | 0.130 |
Why?
| | Preventive Health Services | 1 | 2020 | 154 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.130 |
Why?
| | Zimbabwe | 2 | 2016 | 76 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2018 | 48 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1135 | 0.130 |
Why?
| | Femur Head | 1 | 2018 | 45 | 0.130 |
Why?
| | Metagenomics | 1 | 2019 | 154 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 540 | 0.130 |
Why?
| | Dysbiosis | 1 | 2019 | 184 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 568 | 0.130 |
Why?
| | Healthy Volunteers | 1 | 2018 | 218 | 0.130 |
Why?
| | Movement | 1 | 2019 | 290 | 0.130 |
Why?
| | Gait | 1 | 2020 | 322 | 0.120 |
Why?
| | Phenotype | 3 | 2026 | 3206 | 0.120 |
Why?
| | Diagnostic Errors | 2 | 2015 | 178 | 0.120 |
Why?
| | Alcohol Drinking | 1 | 2024 | 850 | 0.120 |
Why?
| | Drug Discovery | 1 | 2018 | 154 | 0.120 |
Why?
| | Dogs | 2 | 2015 | 517 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 276 | 0.120 |
Why?
| | Glucose | 1 | 2022 | 1053 | 0.120 |
Why?
| | Disease Susceptibility | 1 | 2018 | 339 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1224 | 0.120 |
Why?
| | Drug Combinations | 1 | 2017 | 400 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2023 | 947 | 0.110 |
Why?
| | Attention | 1 | 2019 | 463 | 0.110 |
Why?
| | Machine Learning | 1 | 2021 | 594 | 0.110 |
Why?
| | Human Activities | 1 | 2015 | 19 | 0.110 |
Why?
| | Disease Vectors | 1 | 2015 | 15 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2022 | 881 | 0.110 |
Why?
| | Adolescent | 7 | 2025 | 22557 | 0.110 |
Why?
| | Myalgia | 1 | 2015 | 13 | 0.110 |
Why?
| | Pseudomonas | 1 | 2015 | 30 | 0.110 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 43 | 0.110 |
Why?
| | Diet | 2 | 2022 | 1273 | 0.110 |
Why?
| | Puerto Rico | 2 | 2025 | 64 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 866 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2113 | 0.110 |
Why?
| | Microbiological Techniques | 1 | 2014 | 30 | 0.100 |
Why?
| | Dideoxynucleosides | 1 | 2014 | 27 | 0.100 |
Why?
| | Genetic Markers | 1 | 2015 | 340 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 474 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1133 | 0.100 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 38 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 114 | 0.100 |
Why?
| | Computational Biology | 1 | 2019 | 678 | 0.100 |
Why?
| | Herpesvirus 8, Human | 1 | 2014 | 67 | 0.100 |
Why?
| | Fever | 1 | 2015 | 322 | 0.100 |
Why?
| | Dog Diseases | 1 | 2015 | 140 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 18 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2016 | 322 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 153 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 251 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 996 | 0.100 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.090 |
Why?
| | Lopinavir | 1 | 2013 | 30 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 846 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2026 | 3034 | 0.090 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 100 | 0.090 |
Why?
| | Radiography | 1 | 2015 | 861 | 0.090 |
Why?
| | Neoplasms | 2 | 2019 | 2954 | 0.090 |
Why?
| | Regression Analysis | 1 | 2015 | 999 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 429 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 779 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.090 |
Why?
| | Computer Simulation | 2 | 2026 | 1014 | 0.080 |
Why?
| | Oligopeptides | 1 | 2013 | 264 | 0.080 |
Why?
| | Outpatients | 1 | 2014 | 440 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1503 | 0.080 |
Why?
| | Visual Acuity | 1 | 2014 | 499 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5439 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1957 | 0.080 |
Why?
| | Pregnancy | 1 | 2023 | 7230 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 495 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1148 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1107 | 0.070 |
Why?
| | Research Design | 2 | 2025 | 1143 | 0.070 |
Why?
| | Pyridines | 1 | 2013 | 610 | 0.070 |
Why?
| | Linezolid | 1 | 2008 | 25 | 0.070 |
Why?
| | Interviews as Topic | 2 | 2024 | 930 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2019 | 226 | 0.070 |
Why?
| | Animals | 3 | 2021 | 38107 | 0.060 |
Why?
| | Baltimore | 1 | 2025 | 71 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2026 | 122 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3416 | 0.050 |
Why?
| | Missouri | 1 | 2024 | 66 | 0.050 |
Why?
| | Bias | 1 | 2025 | 197 | 0.050 |
Why?
| | Mortality | 2 | 2019 | 375 | 0.050 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2023 | 9 | 0.050 |
Why?
| | Registries | 2 | 2024 | 2400 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 368 | 0.050 |
Why?
| | Ohio | 1 | 2023 | 136 | 0.050 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.050 |
Why?
| | Intention | 1 | 2024 | 187 | 0.050 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 195 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 585 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 507 | 0.050 |
Why?
| | Nucleosides | 1 | 2022 | 25 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 147 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2022 | 25 | 0.050 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2022 | 89 | 0.040 |
Why?
| | Pharmacogenetics | 1 | 2023 | 176 | 0.040 |
Why?
| | Cocaine | 1 | 2024 | 162 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2023 | 134 | 0.040 |
Why?
| | Concept Formation | 1 | 2022 | 31 | 0.040 |
Why?
| | Faculty | 1 | 2023 | 152 | 0.040 |
Why?
| | Habits | 1 | 2022 | 47 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 266 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 223 | 0.040 |
Why?
| | Overweight | 1 | 2026 | 614 | 0.040 |
Why?
| | Citric Acid | 1 | 2021 | 33 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 80 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2022 | 195 | 0.040 |
Why?
| | Mentors | 1 | 2023 | 217 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2022 | 0.040 |
Why?
| | New York City | 1 | 2020 | 89 | 0.040 |
Why?
| | Heart Failure | 1 | 2014 | 2329 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1149 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 104 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 328 | 0.040 |
Why?
| | Europe | 1 | 2021 | 421 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 68 | 0.040 |
Why?
| | Marijuana Use | 1 | 2023 | 218 | 0.040 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2019 | 15 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 97 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 790 | 0.040 |
Why?
| | Antitubercular Agents | 1 | 2021 | 212 | 0.040 |
Why?
| | Cardiorespiratory Fitness | 1 | 2020 | 73 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 766 | 0.040 |
Why?
| | Hip Fractures | 1 | 2020 | 88 | 0.040 |
Why?
| | Health Behavior | 1 | 2024 | 802 | 0.040 |
Why?
| | Demography | 1 | 2019 | 274 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 171 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2019 | 84 | 0.030 |
Why?
| | Geriatrics | 1 | 2019 | 96 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 467 | 0.030 |
Why?
| | AIDS-Associated Nephropathy | 1 | 2018 | 7 | 0.030 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 20 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 465 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2018 | 49 | 0.030 |
Why?
| | Psychometrics | 1 | 2022 | 712 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2023 | 1051 | 0.030 |
Why?
| | Models, Statistical | 1 | 2022 | 669 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2019 | 219 | 0.030 |
Why?
| | Hair | 1 | 2018 | 81 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2023 | 801 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 881 | 0.030 |
Why?
| | RNA | 1 | 2023 | 926 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3930 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 60 | 0.030 |
Why?
| | Haiti | 1 | 2016 | 13 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 20 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 908 | 0.030 |
Why?
| | Menopause | 1 | 2019 | 328 | 0.030 |
Why?
| | Research | 1 | 2019 | 421 | 0.030 |
Why?
| | Peru | 1 | 2016 | 61 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 58 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1075 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 511 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 424 | 0.030 |
Why?
| | Brazil | 1 | 2016 | 179 | 0.030 |
Why?
| | India | 1 | 2016 | 213 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 574 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7109 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1221 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 262 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1543 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 614 | 0.030 |
Why?
| | Wisconsin | 1 | 2014 | 102 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 827 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2016 | 137 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 319 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2017 | 533 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2015 | 422 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 405 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4093 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1272 | 0.020 |
Why?
| | Brain | 1 | 2021 | 2991 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 1498 | 0.010 |
Why?
|
|
Erlandson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|